Porcine Parts on the Horizon?

Frontlines | Porcine Parts on the Horizon? Courtesy of Scott Bauer Infigen of DeForest, Wis., and BioTransplant of Charlestown, Mass., recently announced the birth of three pigs that mark the next stop on road toward xenotransplantation. The minipigs are clones derived from previous research (J. Betthauser et al., "Production of cloned pigs from in vitro systems," Nat Biotech, 18:1055-9, 2000) as well as knockouts for alpha-1,3-galactosyltransferase (GGTA1), which normally places a particu

Written byRicki Lewis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Infigen of DeForest, Wis., and BioTransplant of Charlestown, Mass., recently announced the birth of three pigs that mark the next stop on road toward xenotransplantation. The minipigs are clones derived from previous research (J. Betthauser et al., "Production of cloned pigs from in vitro systems," Nat Biotech, 18:1055-9, 2000) as well as knockouts for alpha-1,3-galactosyltransferase (GGTA1), which normally places a particular carbohydrate onto cell surfaces. "Human cells do not have this carbohydrate on their surfaces, and thus reject tissues whose cells do. Knocking out GGTA1 prevents the addition of this carbohydrate," explains Erik J. Forsberg, Infigen's vice president of development.

The pigs, no-named but numbered, aren't the first swine to serve as a bridge to transplantation. In 1997, 19-year-old Robert Pennington survived acute liver failure long enough to undergo a transplant, thanks to Sweetie Pie, a 15-week-old, 118-pound pig. Pennington's blood was cleansed as it circulated through the pig's disembodied ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies